Diffuse Dermal Angiomatosis of the Breast

Diffuse dermal angiomatosis is rare and usually considered a variant of reactive angioendotheliomatosis. It generally involves the extremities of patients with severe vascular disease and other comorbidities. Two patients with…Continue readingDiffuse Dermal Angiomatosis of the Breast

Targeted therapy

Targeted therapy is a type of cancer treatment that works differently to chemotherapy. Chemotherapy attacks all rapidly dividing cells in the body, but targeted therapy works by “targeting” those differences that…Continue readingTargeted therapy

Cancer treatment centres in Nepal

1.   B. P. Koirala Memorial Cancer Hospital (BPKMCH): BPKMCH is the first tertiary level cancer hospital in Nepal, which provides all types of cancer treatment services, such as surgical oncology,…Continue readingCancer treatment centres in Nepal

Treatment of breast cancer

Treatments are less invasive when breast cancer is detected at an early stage. Challenges for breast cancer treatment in Nepal include patient’s financial status (given the huge out-of-pocket expenditure), accessibility…Continue readingTreatment of breast cancer

Disclaimer

Disclaimer Articles, videos, online books, pictures,online videos, Exam Information, MCQs and Related topics in this medicospase is entirely intended  for study and general information purpose . Medicine and its updates…Continue readingDisclaimer

Medicospace mederna

Moderna Covid-19 vaccine generates Immune response is a good news

Moderna Covid-19 vaccine generates Immune would be good news to all over the world.  It is good to know that Moderna is developing the vaccine in conjunction with the NIAID’s Vaccine Research Center.

ovid-19 vaccine generates Immune response
COVID-19 vaccine generates Immune response

The drugmaker Moderna company has said that it appears to generate an immune response similar to the response seen in people who have been infected by the virus and recovered. This trail was done on a small number of participants in the trial, led by the National Institute of Allergy and Infectious Diseases

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 μg,” said Tal Zaks, Moderna’s chief medical officer

During the Phase 1 trial, eight patients received two doses of the vaccine at the lowest and middle doses tested as 25 and 100 micrograms. They developed neutralizing antibodies against the virus at levels similar to people who had recovered from infection.  Though data were limited these results are still likely to be seen as encouraging. The research aimed to develop a vaccine against SARS, a related virus responsible for a 2002-2003 outbreak, showed that neutralizing antibodies are pivotal for achieving protection.

Source: Stat News

Leave a Reply